Retroscreen Virology Secures £2.6 Million for Antiviral Therapies

Retroscreen Virology, a London-based biotechnology company focused on antiviral therapies for emerging viral diseases, has raised £2.6 million in Series A funding

The company utilizes a proprietary technology platform based on human genetics to identify and validate novel targets for drug discovery

This funding will be used to further develop its pipeline of antiviral therapies and expand its research and development activities.